Skip to the page

Data / Drug companies / Sun Pharmaceutical Industries, Inc.

Sun Pharmaceutical Industries, Inc.: 66 products in the FDA NDC directory, labeler code 63304

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Sun Pharmaceutical Industries, Inc. (labeler code 63304) lists 66 products in the FDA National Drug Code Directory, covering 24 finished drugs by generic name. By type: 64 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 30, 2026.

The request: Watch Sun Pharmaceutical Industries, Inc. (FDA labeler code 63304): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
63304
Products in commercial distribution
66
Packages
156
Finished drugs by generic name
24
Prescription products
64
Over the counter products
2
Controlled substance products
Schedule II 5, Schedule IV 4
Flagged as original packager
44 of 44 products that carry the flag
Started marketing in the last 12 months
4
Products with a marketing end date set
1
Earliest marketing start
December 26, 2000
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)5786.4%
New drug applications (NDA)710.6%
Authorized generics (NDA)23%

Products by type

TypeProductsShare
Prescription drugs6497%
Over the counter drugs23%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Capsule2030.3%
Tablet, film coated913.6%
Capsule, extended release812.1%
Tablet, film coated, extended release812.1%
Tablet, extended release69.1%
Tablet, orally disintegrating57.6%
Tablet46.1%
Capsule, gelatin coated23%
Capsule, delayed release23%
Tablet, coated11.5%
Tablet, delayed release11.5%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Dextromethorphan Hydrobromide and Quinidine Sulphate63304-650CapsuleGeneric drugs (ANDA)July 30, 2026
Dapagliflozin and Metformin Hydrochloride63304-028Tablet, film coated, extended releaseGeneric drugs (ANDA)April 6, 2026
Dapagliflozin and Metformin Hydrochloride63304-027Tablet, film coated, extended releaseGeneric drugs (ANDA)April 6, 2026
Dapagliflozin and Metformin Hydrochloride63304-026Tablet, film coated, extended releaseGeneric drugs (ANDA)April 6, 2026
Esomeprazole magnesium63304-735Capsule, delayed releaseGeneric drugs (ANDA)September 18, 2025
Esomeprazole magnesium63304-734Capsule, delayed releaseGeneric drugs (ANDA)September 18, 2025
Potassium Chloride63304-987Tablet, extended releaseGeneric drugs (ANDA)November 14, 2023
Pazopanib63304-116Tablet, film coatedGeneric drugs (ANDA)October 20, 2023
Lorazepam63304-774TabletGeneric drugs (ANDA)June 25, 2023
Lorazepam63304-773TabletGeneric drugs (ANDA)June 25, 2023
Lorazepam63304-772TabletGeneric drugs (ANDA)June 25, 2023
Lenalidomide63304-045CapsuleGeneric drugs (ANDA)March 12, 2023
Lenalidomide63304-041CapsuleGeneric drugs (ANDA)March 12, 2023
Lenalidomide63304-046CapsuleGeneric drugs (ANDA)March 4, 2023
Lenalidomide63304-044CapsuleGeneric drugs (ANDA)March 4, 2023
Lenalidomide63304-043CapsuleGeneric drugs (ANDA)March 4, 2023
Lenalidomide63304-042CapsuleGeneric drugs (ANDA)March 4, 2023
Lubiprostone63304-352Capsule, gelatin coatedAuthorized generics (NDA)January 1, 2023
Lubiprostone63304-351Capsule, gelatin coatedAuthorized generics (NDA)January 1, 2023
Mesalamine63304-089Capsule, extended releaseGeneric drugs (ANDA)May 13, 2022
Guaifenesin and Dextromethorphan HBr63304-110Tablet, extended releaseGeneric drugs (ANDA)July 1, 2021
Guaifenesin and Dextromethorphan HBr63304-106Tablet, extended releaseGeneric drugs (ANDA)July 1, 2021
Droxidopa63304-112CapsuleGeneric drugs (ANDA)February 18, 2021
Droxidopa63304-104CapsuleGeneric drugs (ANDA)February 18, 2021
Droxidopa63304-086CapsuleGeneric drugs (ANDA)February 18, 2021

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.